The 2024 American Clinical Chemistry Annual Meeting and Clinical Laboratory Medicine Expo (ADLM) took place in Chicago, USA, from July 30 to August 1. B&E showcased its innovative products to both new and existing international clients, including the i-check handheld blood gas analyzer, KS402 fully automatic high-speed electrolyte analyzer, Hemax53+FI five-part differential hematology and fluorescence immunoassay integrated machine, and the HPLC-based HbA1c analyzer. Among these, the single-use, handheld blood gas-specific reagent card, developed using biotechnology and microfluidics, is at the forefront of global technology.
B&E has been recognized as a National-level Specialized, Refined, Unique, and Innovative Small Giant, a pioneer in research and development within the domestic IVD reagent field. The company possesses the capability to develop and produce all reagents compatible with major international brand hematology analyzers and has played a significant role in breaking foreign monopolies by providing domestic alternatives. All of B&E's hematology reagents have been registered with the US FDA and are exported to over 60 countries, enjoying a high level of recognition and market share.
The three- and five-part differential hematology analyzers are a traditional strength of B&E. To broaden the application scope and better meet user needs, the company innovatively added fluorescence immunoassay capabilities to the Hemax53. Currently, the system supports combined blood routine and CRP+SAA testing, with plans to introduce more immunoassay tests in the future. This new product has been installed in several hospitals in China and has received positive feedback from users.
In recent years, leveraging leading biosensor technology, B&E has launched and continuously upgraded the CBS and KS series of electrolyte analyzers, which feature maintenance-free electrodes. These analyzers ensure reliable accuracy and stability while providing users with simpler operation and maintenance and more diverse application scenarios. They are widely recognized as the next-generation standard in electrolyte analysis, with their global market share steadily increasing.
The handheld blood gas analyzer, crafted by B&E, attracted attention and praise from international clients at the expo. The analyzer offers a wide range of cards covering blood gas, electrolytes, and biochemistry parameters, meeting the unique demands for rapid, flexible, and convenient blood gas testing in critical care and emergency settings. Currently, only Abbott and Siemens have similar products on the international market. Comparative and validation studies show that the B&E i-check handheld blood gas analyzer has high reliability in terms of accuracy and precision, with superior performance in reagent card longevity and ease of use compared to competitors. Its unique competitive edge fills a gap domestically and will undoubtedly stir up another wave of Chinese innovation in the global IVD blood gas analysis market.
